Diabetes, the disease which destroys the natural ability of the body to transform food into energy, has been the source of millions of deaths every year worldwide. The economic impacts of this major healthcare issue can never be underpinned by major stakeholders of the industry.
The recent slump of the diabetes drugs industry brought about by the side effects of previous treatments has caused major players to innovate in their approaches towards medical research and development. More than economic profitability, the growing lucrative industry is finding ways on how to improve the conditions of medical treatments and provide cost-effective remedies as soon as possible.
Multinational companies are being pushed to fuel the urge in advancing research and developments of medicines and appropriate treatment. The main goal of pharmaceutical companies now is to reduce or bring to negligible intensity the side effects of controlling blood-sugar levels, as well as reduce the costs associated in producing these drugs. With high levels of sugar in average individual and low amounts of insulin to convert food into energy, side effects can potentially be life threatening. Released from 2006 to 2007, inhalable insulin devices from known brands are continuously being perfected and innovated to provide comfortable insulin intake relative to subcutaneous or intravenous injections. In addition, the introduction of intranasal devices, which are products delivering insulin though the nose and not the lungs, are still being experimented and may be perfected for the market in few years time.
With the need to provide alternative choices for diabetic patients, industry stakeholders will always be searching for innovative approaches in medical research. Rest assured it is the ultimate goal of pharmaceutical companies to create better medicines and treatments with significantly lesser side effects at lower costs.